Although premenstrual syndrome (PMS) and menopause are distinct physiological stages, they share a common denominator: periods of significant hormonal change that affect many of the same biological pathways involved in emotional disturbances, sleep, stress response and overall well-being.
This common ground is particularly relevant when considering how women experience symptoms.
During PMS, fluctuations in oestrogen and progesterone recur with each menstrual cycle.
During perimenopause, hormonal fluctuations become progressively more irregular as the body transitions towards menopause.
The timing and pattern differ … but biological sensitivity to changing hormone levels can overlap.
This may explain why women can experience similar physical and psychological symptoms at very different life stages.
When hormones fluctuate, multiple pathways can be affected
Hormonal changes do not occur in isolation. Fluctuations in oestrogen and progesterone influence several interconnected biological systems, including the neurotransmitters involved in emotional regulation, such as serotonin, as well as the body’s stress response and inflammatory processes.
Research also highlights the relationship between hormonal changes, the gut microbiota and the gut-brain axis, adding another layer to the complex communication between the brain, the digestive system and the rest of the body.
The overlap between PMS and perimenopausal symptoms raises an important question: could supporting the biological pathways affected by hormonal fluctuations help women to navigate both periods of transition?
A solution for two common problems
According to market insights, saffron is the fastest-growing ingredient in women’s health.1
But as saffron moves from an emerging trend to a mainstream ingredient, the next question is not simply why saffron? But which saffron?
Safr’Inside™ combines extract characterisation with a growing body of scientific and clinical research.
It is a patented saffron extract that’s standardised to the highest and precisely quantified content of safranal (≥0.2%, measured by UHPLC), which contributes to its fast effects and benefits.
Activ’Inside has identified six complementary mechanisms of action that contribute to its efficacy, including the modulation of serotonin pathways, the stress response, inflammatory processes and the gut microbiota.
Most recently, two clinical studies have investigated Safr’Inside™ in women experiencing PMS and perimenopausal symptoms, providing a unique perspective on how one botanical may support women during two distinct but biologically connected stages of hormonal change.
Evidence in PMS: In a randomised, double-blind, placebo-controlled study, supplementation with 30 mg/day of Safr’Inside™ for three menstrual cycles significantly reduced overall PMS symptom severity compared with a placebo.
Improvements were observed from the first cycle, with significant benefits reported after just 7 days.
Evidence during menopause: Research in healthy women experiencing perimenopausal symptoms has also shown promising results.
After 12 weeks of Safr’Inside™ supplementation, the total Greene Climacteric Scale (GCS) score was reduced significantly (68% from baseline) compared with a placebo.
Improvements were also observed in night sweats, emotional disturbances and vitality. Benefits became clinically relevant from week 6 and continued to increase through week 12.
PMS and perimenopause are distinct conditions that occur at different stages of life and involve different hormonal patterns.
Yet both illustrate how hormonal fluctuations can influence interconnected systems that contribute to emotional disturbances, sleep, stress and overall well-being.
By acting on multiple pathways involved in serotonin signalling, stress response, inflammation and the gut-brain axis, Safr’Inside™ may support several dimensions of women’s well‑being during periods of hormonal change.
